Inventurus Knowledge Solutions Limited has announced its earnings conference call to discuss Q3 FY 2025-26 results. The company filed the disclosure with stock exchanges on January 27, 2026, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Details

The earnings call has been scheduled with comprehensive access arrangements for participants across different regions.

Regulatory Compliance

The disclosure was submitted to both major Indian stock exchanges where the company is listed. Company Secretary and Compliance Officer Sameer Chavan signed the regulatory filing, which was digitally authenticated on January 27, 2026, at 18:11:03 +05'30'.

Investor Access Options

The company has arranged multiple participation methods for the earnings call. Investors can join through universal dial-in numbers or utilize international toll-free numbers from USA, UK, Singapore, and Hong Kong. Additionally, online participation options are available through participant links and Diamond Pass registration.

Contact Information

For investor relations queries, participants can reach out to Saransh Mundra at investor_relations@ikshealth.com . The comprehensive access arrangements demonstrate the company's commitment to providing transparent communication with its investor community regarding Q3 FY 2025-26 financial performance.

Inventurus Knowledge Solutions Limited has announced the grant of 525,000 employee stock options to eligible employees under its Employee Stock Option Plan 2022. The Nomination and Remuneration Committee of the Board of Directors approved this grant on January 22, 2026, in compliance with SEBI regulations.

ESOP Grant Details

The company disclosed that the stock options have been granted in two separate tranches with different pricing structures and terms. The grant represents a significant employee incentive initiative under the company's established ESOP framework.

The exercise price for the first tranche of 420,000 options is set at ₹1,664.30 per option, which equals the closing price on January 21, 2026, on the National Stock Exchange of India Limited. The second tranche of 105,000 options carries an exercise price of ₹320.00 per option as determined by the Nomination and Remuneration Committee.

Exercise Terms and Conditions

The stock options come with different exercise timeframes depending on the tranche. The first tranche allows options to be exercised anytime during the entire period of continuous active employment from the date of vesting. The second tranche has a more restrictive timeline, requiring exercise within the same calendar year as the vesting date.

Each option, when exercised, will be converted into one fully paid-up equity share with a face value of ₹1.00. The ESOP Plan is administered through a trust structure and includes comprehensive provisions for various employment scenarios including death, permanent incapacity, resignation, termination, and retirement.

Regulatory Compliance and Structure

The grant complies with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, and disclosure requirements under Regulation 30 of the SEBI LODR. The company has made the necessary regulatory filings with both BSE Limited and National Stock Exchange of India Limited.

The ESOP Plan includes provisions for corporate actions such as rights issues, bonus issues, stock splits, consolidations, mergers, amalgamations, or other reorganizations. In such cases, appropriate adjustments will be made in accordance with the plan terms. The equity shares allotted upon exercise of the stock options will not be subject to any lock-in restrictions.

Current Status

As of the grant date, no options have been vested or exercised under this allocation. The disclosure indicates that items such as money realized from exercise, shares arising from exercise, lapsed options, and diluted earnings per share are not applicable at this stage, as the options are newly granted and have not yet reached vesting or exercise phases.